Cell therapy for tendinitis, experimental and clinical report.
To compare cultured bone marrow mesenchymal cells (cBMSC), bone marrow mononucleated cells (BMMNCs), and placebo to repair collagenase-induced tissue damage in an equine model of experimental tendonitis, 6 Standardbred horses with no signs of previous SDF tendon injury have been recruited. Three weeks after collagenase treatment an average of either 5.5 x 10(6) cBMSCs or 122.3 x 10(6) BMMNCs, saline solution (placebo) or fibrin glue were injected intralesionally in random order. Horses were stall rested for 21 weeks, and tendon ultrasound scans performed before and during this period. Horses were euthanized and tendons harvested for histology and immunohistochemistry. Data observed in this study showed effectiveness of cBMSC and BMMNC in regenerating tendon tissue after collagenase -induced tendonitis. Both cBMSC and BMMNC transplantation resulted in qualitatively similar regeneration of tendon extracellular matrix in terms of type I/III collagen ratio, fiber orientation, and COMP expression. After this favourable results, 20 horses were recruited referred for spontaneous lesions of the flexor tendons or the suspensory ligament. Horses were treated with autologous graft of BMMNCs.After treatment the. the exercise program allowed was 8 weeks stall rest, 4 weeks hand walking, 4 weeks trotting, 4 weeks of gradually raising of exercise level then horses were gone back to race. US characteristics of lesions started to improve at T3. CSA-l, FPS and TLS were better in all patients, with an appreciable filling of lesions indicated by a decreasing of CSA-l and increasing of TLS. When horses started the exercise program T8 tendon architecture improved, demonstrated by their longitudinal alignment and length. At T6, and persistently in later follow-up, no lameness was evident by clinical examination. At time of writing 12 patients (60%) were go back to races, while other 8 (40%) are under controlled exercise program. Re-injury rate was assessed at 25%. All the owners judged good to excellent the outcome in term of athletic success.
Lacitignola
L
L
Dipartimento Scienze Cliniche Veterinarie, Teramo, Italy.
Crovace
A
A
Rossi
G
G
Francioso
E
E
D000818:Animals; D016026:Bone Marrow Transplantation / Q000662:veterinary*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods* / Q000662:veterinary; D015718:Fibrin Tissue Adhesive / Q000627:therapeutic use; D006734:Horse Diseases / Q000601:surgery / Q000628:therapy; D006736:Horses; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods / Q000662:veterinary*; D012756:Sheep; D012757:Sheep Diseases / Q000601:surgery / Q000628:therapy; D052256:Tendinopathy / Q000601:surgery / Q000628:therapy* / Q000662:veterinary*; D016896:Treatment Outcome
D015718:Fibrin Tissue Adhesive